Diabetes mellitus is associated with increased prevalence of latent tuberculosis infection:

Results from the National Health and Nutrition Examination Survey

AUTHORS: Marissa M. Barron, MPH^a, Kate M. Shaw, PhD^b, Kai McKeever Bullard, PhD^b,
Mohammed K. Ali, MBChB^c, Matthew J. Magee, PhD^a

AUTHOR AFFILIATIONS:

- a. Division of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, GA, USA
- b. US Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- c. Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

KEYWORDS: latent tuberculosis infection; diabetes mellitus; obesity; tuberculosis

CORRESPONDING AUTHOR:

Matthew J. Magee, PhD, MPH
One Park Place NE
Atlanta, GA 30303
Email: mjmagee@gsu.edu
Phone: 404 413 1797

ALTERNATE AUTHOR:

Marissa M. Barron, MPH
140 Decatur Street
Atlanta, GA 30303
Email: mbarron5@student.gsu.edu
Phone: 478 954 7810

ABSTRACT

Aims: We aimed to determine the association between prediabetes and diabetes with latent TB using National Health and Nutrition Examination Survey data.

Methods: We performed a cross-sectional analysis of 2011-2012 National Health and Nutrition Examination Survey data. Participants ≥ 20 years were eligible. Diabetes was defined by glycated hemoglobin (HbA1c) as no diabetes ($\leq 5.6\%$ [38 mmol/mol]), prediabetes (5.7-6.4% [39-46 mmol/mol]), and diabetes ($\geq 6.5\%$ [48 mmol/mol]) combined with self-reported diabetes. Latent TB infection was defined by the QuantiFERON®-TB Gold In Tube (QFT-GIT) test. Adjusted odds ratios (aOR) of latent TB infection by diabetes status were calculated using logistic regression and accounted for the stratified probability sample.

Results: Diabetes and QFT-GIT measurements were available for 4,958 (89.2%) included participants. Prevalence of diabetes was 11.4% (95%CI 9.8-13.0%) and 22.1% (95%CI 20.5-23.8%) had prediabetes. Prevalence of latent TB infection was 5.9% (95%CI 4.9-7.0%). After adjusting for age, sex, smoking status, history of active TB, and foreign born status, the odds of latent TB infection were greater among adults with diabetes (aOR 1.90, 95%CI 1.15-3.14) compared to those without diabetes. The odds of latent TB in adults with prediabetes (aOR 1.15, 95%CI 0.90-1.47) was similar to those without diabetes.

Conclusions: Diabetes is associated with latent TB infection among adults in the United States, even after adjusting for confounding factors. Given diabetes increases the risk of active TB, patients with co-prevalent diabetes and latent TB may be targeted for latent TB treatment.

1.1 Introduction

There were 10.4 million incident cases of active tuberculosis (TB) in 2015, and 1.4 million deaths attributable to TB[1]. One-fourth of the global population has prevalent latent tuberculosis infection (LTBI)[2]. Although the lifetime risk of reactivation of LTBI to TB disease only occurs in approximately 10% of infected individuals [3], the risk of progression to TB is higher in individuals with comorbidities, such as HIV[4] and diabetes mellitus[5-11]. Individuals with diabetes have approximately three-times the risk of active TB compared to the general population[6, 8, 10, 12] and 15% of all TB cases are attributed to diabetes[8, 13].

The global diabetes epidemic is steadily increasing[6, 7, 14] and the negative impact of diabetes on TB incidence threatens gains in TB control[15]. In 2014, 415 million adults were living with diabetes, and the prevalence of diabetes is projected to reach 642 million globally by 2040[16]. Additionally, 95% of TB patients reside in low- and middle-income countries, and the largest projected increases in diabetes will occur in these same countries[7, 14].

Although existing evidence has demonstrated a relationship between diabetes and active TB, it is unclear whether diabetes also increases the risk of LTBI. Limited studies that examined the relationship between diabetes and LTBI reported substantial heterogeneity[17] and have not accounted for confounding by clinical comorbidities such as kidney disease or hepatitis[18, 19]. Previous studies that reported an association between diabetes and LTBI were not widely generalizable and mostly have not used reliable measures of diabetes and LTBI[17]. An increased risk of LTBI in patients with diabetes would have major clinical implications for TB and diabetes, especially with the expected increase in global diabetes prevalence. To address the gap in knowledge related to diabetes and LTBI, we aimed to determine the association between

prediabetes and diabetes with LTBI using the National Health and Nutrition Examination Survey (NHANES), a study with data that are representative of the US population.

1.2 Material and Methods

We conducted a cross-sectional study using NHANES 2011-2012 data, the most recent cycle that includes QuantiFERON®-TB Gold In Tube (QFT-GIT) to measure LTBI. Briefly, NHANES is a nationally representative survey of US non-institutionalized civilians that includes an in-person interview followed by a health examination. Details of NHANES methodology have been published previously[20]. In NHANES 2011-2012, 13,431 individuals were selected to participate, 9,756 completed the in-person interview, and 9,338 completed the interview and received an examination[21].

1.2.1 Study Design and Participants

Eligible participants were adults (≥ 20 years) who completed the interview and health examination and had valid QFT-GIT (positive/negative) and diabetes status results. Participants with missing or indeterminate QFT-GIT results were excluded. Participants with missing glycated hemoglobin (HbA1c) and self-reported diabetes status were excluded.

Biological specimen collection was performed in NHANES mobile examination centers (MECs)[20]. Samples were transported to laboratories across the US for processing[22], except samples for QFT-GIT testing, which were processed at a Clinical Laboratory Improvement Act-certified laboratory as previously described[18].

1.2.2 Study Measures and Definitions

Diabetes status of participants was defined by self-reported diabetes status and HbA1c. Participants who self-reported previous diabetes diagnosis by a healthcare professional were classified as having diabetes regardless of HbA1c. Participants without self-reported history of diabetes were classified by HbA1c as no diabetes ($\leq 5.6\%$ [38mmol/mol]), prediabetes (5.7-6.4% [39-46mmol/mol]), or diabetes ($\geq 6.5\%$ [48mmol/mol]) according to the American Diabetes Association guidelines[23]. Participants with diabetes were further classified as having diagnosed or undiagnosed diabetes. Diagnosed diabetes was classified as self-reporting diabetes, and undiagnosed diabetes was classified as self-reporting not having diabetes with HbA1c $\geq 6.5\%$ (48mmol/mol). Among participants with self-reported diabetes, length of time since initial diabetes diagnosis and information regarding diabetes medication were assessed via interview. Self-reported information on use of insulin and oral diabetes agents was collected[24].

QFT-GIT was analyzed according to manufacturer instructions. Results were interpreted according to guidelines from the Centers for Disease Control and Prevention (CDC) for using interferon-gamma release assays (IGRAs)[25]. Participants with positive QFT-GIT results were classified as LTBI positive, participants with negative QFT-GIT results were classified as LTBI negative. Participants with indeterminate QFT-GIT results were classified for this analysis as missing.

Participants who self-reported they had ever been told by a health care professional to have active TB were defined as having a history of active TB. Body mass index (BMI) ranges were categorized as underweight (<18.5), normal weight (18.5-24.9 kg/m²), overweight (25.0-29.9 kg/m²), or obese (≥ 30 kg/m²) according to CDC guidelines[26]. Age ranges were categorized as young adult (20-34 years), middle-aged (35-64 years), or elderly (65 years and

older). Current smokers were defined as participants who self-reported use of 100 cigarettes in their lifetime and self-reported currently smoking, which included smokers reporting use every day or some days. Former smokers were defined as those who reported smoking 100 cigarettes in their lifetime but did not currently smoke cigarettes. Participants who had not smoked 100 cigarettes in their lifetime were defined as never smokers [24, 27].

Urine samples were analyzed for albumin creatinine ratio (ACR), and ACR levels were categorized as normal to mildly increased ($<30\text{mg/g}$), moderately increased ($30\text{-}300\text{mg/g}$), or severely increased ($>300\text{mg/g}$) according to National Kidney Foundation guidelines for albuminuria categories in chronic kidney disease[28]. Hepatitis B virus (HBV) core antibody (anti-HBc) and surface antigen (HBsAg) response were determined using the VITROS Anti-HBc assay and HBsAg assay, respectively; results were defined as positive or negative. The HBsAg assay was only performed for participants that tested positive for anti-HBc; participants with a negative result for anti-HBc were defined as negative for HBsAg. Hepatitis C antibody (anti-HCV) response was determined using the VITROS Anti-HCV assay; results were defined as positive or negative. Non-fasting blood samples were analyzed for total cholesterol and high-density lipoprotein (HDL) cholesterol[24]. Total cholesterol was defined as desirable ($<200\text{mg/dL}$), borderline high ($200\text{-}239\text{mg/dL}$), or high ($\geq 240\text{mg/dL}$) according to National Institutes of Health guidelines[29]. Our study categorized HDL cholesterol levels as major risk factor for heart disease ($<40\text{mg/dL}$), borderline ($40\text{-}59\text{mg/dL}$), or protective against heart disease ($\geq 60\text{mg/dL}$) according to Medline Plus guidelines[30]. Responses of “don’t know” or “refused” were recoded as missing for all variables.

1.2.3 Statistical Analyses

To examine the association between diabetes and LTBI we used bivariate analyses and multivariable logistic regression. The Rao-Scott chi-square test was used to analyze all bivariate associations between participant characteristics and LTBI and diabetes. To examine the prevalence of diabetes and LTBI in the US population, we reported weighted prevalence estimates and 95% confidence intervals (CI). Taylor series method was used to estimate variance for all prevalence estimates[31]. Multivariable logistic regression was used to estimate adjusted odds ratios (aOR) and 95% CI between diabetes and LTBI and were adjusted for potential confounders. Covariates included in multivariable models as confounders were chosen from observed bivariate associations with diabetes and LTBI, previous study findings, and causal model theory (directed acyclic graphs) [32]. In multivariable models, multiplicative statistical interaction was assessed to determine if the association between diabetes and LTBI was modified by obesity or HDL cholesterol. In a subgroup analysis, we also examined the bivariate association between participant characteristics and LTBI only among individuals with diabetes. Analyses were performed using SAS version 9.4 and accounted for the weighted stratified probability sample design of NHANES [33]. Because medical examination data were used during the analyses, we used the weight variable WTMEC2YR to obtain prevalence estimates and measures of association. A two-sided p-value <0.05 was considered statistically significant for all tests.

1.2.4 Sensitivity Analysis

We performed sensitivity analyses to assess potential error due to 1) misclassification of diabetes status and 2) covariate misspecification in multivariable models. To assess diabetes misclassification, we re-examined the diabetes-LTBI association after adding fasting blood glucose (prediabetes 100-125mg/dL, or diabetes $\geq$ 126mg/dL) to our primary diabetes definition

which used self-report and HbA1c only[23]. In the second sensitivity analysis we specified several subsets of adjusted multivariable models to provide a range of plausible aORs and 95%CI for the association between diabetes and LTBI.

1.3 Results

1.3.1 Study Participants

Of 9,756 NHANES 2011-2012 participants, 5,560 (57.0%) were aged 20 years or older and thus eligible for our study. A total of 4,958 (89.2%) participants had both valid QFT-GIT results and information on self-reported diabetes status and/or HbA1c results and were included in these analyses. Before accounting for selection weights, 793 eligible participants had diabetes, 513 had LTBI, and 127 had both diabetes and LTBI.

1.3.2 Prevalence of Diabetes and Latent TB Infection

Our results estimated that the prevalence of diabetes among adults in the United States population was 11.4% (95%CI 9.8-13.0%) and the prevalence of prediabetes was 22.1% (95%CI 20.5-23.8%) (Table 1). The prevalence of diabetes was highest among the elderly (22.9%; 95%CI 19.8-25.9%), people with obesity (20.4%; 95%CI 17.3-23.5%), those with less than a 9th grade education (25.2%; 95%CI 18.2-32.2%), severely increased ACRs (46.9%; 95%CI 33.7-60.1%), hepatitis C (19.8%; 95%CI 7.1-32.5%), and hypertension (23.3%; 95%CI 20.8-25.9%).

Our results estimated that the prevalence of LTBI among adults in the United States was 5.9% (95%CI 4.9-7.0%) (Table 2). Prevalence of LTBI was highest among the elderly (8.8%; 95%CI 6.6-10.9%), the foreign-born (17.2%; 95%CI 14.3-20.0%), those with less than a 9th grade education (17.9%; 95%CI 13.2-22.7%), Hispanics (12.9%; 95%CI 10.4-15.4%), non-Hispanic Asians (20.3%; 95%CI 16.8-23.8%), and those who reported a previous history of

active TB (42.7%; 95%CI 24.1-61.2). LTBI prevalence was also high among those with high (>300mg/g) ACR (12.9%; 95%CI 6.7-19.2%), those who tested positive for anti-HBc (18.0%; 95%CI 11.6-24.4%), and those who tested positive for HBsAg (23.0%; 95%CI 8.2-37.7%).

The prevalence of LTBI was significantly higher among adults with diabetes (11.6%; 95%CI 7.9-15.3%) compared to those without diabetes (4.6%; 95%CI 3.7-5.6%). LTBI prevalence was also higher among those with prediabetes (7.0%; 95%CI 5.2-8.7%) compared to those without diabetes, though the difference was not statistically significant. Adults with diabetes and prediabetes had significantly higher crude odds of LTBI (diabetes: crude OR 2.70; 95%CI 1.76-4.14; prediabetes: crude OR 1.54; 95%CI 1.24-1.91) compared to those without diabetes (Table 3). Reported inversely, among those with LTBI the prevalence of diabetes was 22.2% (95%CI 16.6-27.8%) and the prevalence of prediabetes was 25.9% (95%CI 22.1-29.7%). Among those without LTBI the prevalence of diabetes was 10.7% (95%CI 9.0-12.4%) and the prevalence of prediabetes was 21.9% (95%CI 20.3-23.6%).

1.3.3 Multivariable Models Results

Adults with diabetes had significantly higher odds of LTBI (aOR 1.90; 95%CI 1.15-3.14) compared to adults without diabetes (Table 3) after adjusting for age, sex, smoking status, history of active TB, and foreign born status. Those previously diagnosed with diabetes had significantly higher odds of LTBI (aOR 1.75; 95%CI 1.09-2.80) compared to adults without diabetes, as did adults with previously undiagnosed diabetes (aOR 1.96; 95%CI 1.05-3.68). The odds of LTBI among adults with prediabetes (aOR 1.15; 95%CI 0.90-1.47) was not significantly higher than among adults without diabetes.

We found no indication of significant multiplicative interaction. Although not significantly different from each other, the association between diabetes and LTBI tended to be greater among those with obesity (aOR 2.22; 95%CI 1.08-4.54) compared to those without obesity (aOR 1.48; 95%CI 0.85-2.58) (data not shown). Similarly, the association between diabetes and LTBI was non-significantly greater among those with higher HDL (≥ 60 mg/dL) levels (aOR 2.77; 95%CI 1.13-6.84) compared to those with lower HDL (< 60 mg/dL) levels (aOR 1.80; 95%CI 0.99-3.29).

1.3.4 Subgroup Analysis of Adults with Diabetes

Among adults with diabetes, an estimated 19.9% (95%CI 15.3-24.4%) were previously undiagnosed (Table 4). Prevalence of LTBI was non-significantly (p-value=0.24) different among adults with previously undiagnosed diabetes (14.4%; 95%CI 6.7-22.2%) compared to adults who had been previously diagnosed (10.9%; 95%CI 7.4-14.4%). LTBI prevalence was significantly higher (p-value=0.03) among adults who reported not using insulin (12.9%; 95%CI 8.5-17.3%) compared to adults who reported using insulin (7.3%; 95%CI 3.1-11.4%). Among those with diabetes, LTBI prevalence was found to be highest among Hispanics (24.3%; 95%CI 12.4-36.2%), non-Hispanic Asians (27.5%; 95%CI 19.0-35.9%), those born outside of the United States (30.2; 95%CI 18.8-41.6%), and those with a positive test result for anti-HBc (20.8%; 95%CI 8.9-32.7%).

1.3.5 Sensitivity Analyses

In our sensitivity analysis to assess potential misclassification of diabetes using FBG in addition to self-report and HbA1c, adults with diabetes had significantly higher crude odds of LTBI (crude OR 2.43; 95%CI 1.32-4.49) compared to those without diabetes (data not shown).

Adults with prediabetes had non-significantly higher crude odds of LTBI (crude OR 1.21; 95%CI 0.74-2.00) compared to those without diabetes. After adjusting for age, sex, smoking status, history of active TB, and foreign born status, adults with diabetes had a non-significant higher odds of LTBI (aOR 1.36; 95%CI 0.70-2.65) compared to those without diabetes.

In our sensitivity analysis to assess covariate misspecification of adjusted models, we found adjusted odds ratios that ranged from 1.49 (95%CI 0.83-2.68) to 2.20 (95%CI 1.22-3.96) for the odds of LTBI in adults with diabetes compared to those without diabetes (Supplemental Table 1). We found adjusted odds ratios that ranged from 0.95 (95%CI 0.75-1.21) to 1.25 (95%CI 0.93-1.68) for the odds of LTBI in adults with prediabetes compared to those without diabetes; however, none were statistically significant.

1.4 Conclusions

We used data nationally representative of the US population to examine the association between LTBI and diabetes and found a robust relationship between the two diseases. We reported that the prevalence of LTBI among adults with diabetes was more than twice the prevalence of those without diabetes. Similarly, we found that more than one-fifth of adults with LTBI had diabetes. We did not find significant differences in LTBI prevalence among those who were previously diagnosed compared to those who were previously undiagnosed. We also did not find significant differences in LTBI prevalence among those with prediabetes compared to those without diabetes. To our knowledge, this study is the largest and most generalizable analysis to compare the prevalence of LTBI among adults with and without diabetes and prediabetes.

Our results are consistent with the findings of previous studies. In a systematic review conducted by Lee et al., the meta-analysis included findings from one cohort study and 12 cross-sectional studies investigating the association between diabetes and LTBI. From the 12 cross-sectional studies, researchers calculated a pooled odds ratio of 1.18 (95%CI 1.06-1.30), indicating a slight yet significant increased odds of LTBI among patients with diabetes compared to patients without diabetes[17]. A limitation of several studies reviewed in Lee et al.'s systematic review and meta-analysis was the potential misclassification of LTBI due to measurement error associated with the TST (tuberculin skin test). Unlike many previous studies, our study relied upon the use of QFT-GIT which is not affected by the Bacillus Calmette-Guérin (BCG) vaccine. Our national estimates of LTBI prevalence were similar to previously reported estimates[18, 34].

Our results were similar to a study conducted by Hensel et al. in the metropolitan area of Atlanta, Georgia[5]. This study also utilized both HbA1c and QFT-GIT to determine diabetes status and LTBI status, respectively. Hensel et al. found a nearly doubled prevalence of LTBI among patients with diabetes compared to those without diabetes[5]. Unlike our study, however, the Atlanta study was not generalizable to the US adult population, as it only included recently arrived refugees to the US[5]. As with the Atlanta study, we found no significant difference in the prevalence of LTBI among patients with previously undiagnosed diabetes compared to those with previously diagnosed diabetes[5].

Although the causal mechanisms that result in increased co-occurrence of LTBI and diabetes remain to be definitively established, there are relevant biologic hypotheses that may explain how diabetes may increase the risk of LTBI and vice-versa. Some LTBI granulomas on the spectrum of high MTB activity include bacterial replication and likely result in proximal

immune signaling, a phenomena which may persist in adipose tissue[35]. Secretion of pro-inflammatory adipokines and cytokines within adipocytes could interfere with insulin regulation and contribute to diabetes risk[36]. If LTBI contributes to immune activation within visceral adipose tissue, it would likely increase the risk of diabetes or prediabetes. Alternatively, chronic low-grade inflammation and immunopathology associated with diabetes and prediabetes [37] may contribute to susceptibility to TB infection[9, 10].

Our study was subject to several limitations. First, there may have been misclassification of participant characteristics. For example, self-reported information on smoking status was determined via participant responses to a questionnaire, so smokers may have reported not smoking due to social stigma. While diabetes and LTBI status may also be subject to misclassification, we defined these primary study variables using currently recommended clinical measures (HbA1c and QFT-GIT)[38, 39]. By using the QFT-GITs instead of the TST to measure LTBI, we avoided potential cross-reaction with antigens found in the BCG vaccine, commonly used outside the United States [39]. However, we did not account for discordance between QFT-GIT and TST, and therefore some misclassification of LTBI may have occurred. Second, in this study we were unable to adjust for the probability being exposed to someone with active TB. Although previous history of active TB was assessed via questionnaire and found to be associated with LTBI but not diabetes status, the inability to adjust for probability of exposure to TB may have distorted our estimated association between LTBI and diabetes. Nonetheless, we did adjust for several other key confounding factors such as smoking, age, and foreign born status. We also were able to assess the distribution of other underlying infections, such as hepatitis B and C and kidney disease, and found no evidence of confounding. Third, our study was a cross-sectional design, and as such we were unable to determine the temporal relationship

between LTBI and diabetes. For example, our results are unable to differentiate whether the observed association was due to an increased risk of LTBI from diabetes or if LTBI may increase the risk of diabetes. Longitudinal studies are needed to investigate the temporal association between LTBI and diabetes.

This study reported that diabetes was significantly associated with an increased odds of LTBI prevalence in US adults, even after adjusting for key confounding factors. Overall, more than one-fifth of all adults with LTBI had diabetes. Information from this study greatly improves our understanding of the intersection of the TB and diabetes epidemics. With the increasing prevalence of diabetes in areas with the highest burden of TB, targeted efforts may be needed to address the co-infection of diabetes and LTBI to prevent an increase in TB incidence worldwide.

1.5 Acknowledgements

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). The use of trade names and commercial sources is for identification only and does not imply endorsement by the CDC. Author contributions: MJM, MMB, KMB, and MKA conceived and designed the study and drafted the initial manuscript. MMB, KMS, and MJM performed the data analyses. All authors contributed to interpretation of the data, revised the manuscript, and approved the final version.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. World Health Organization. Global Tuberculosis Report 2015. **2015**; 20: 1-4.
2. Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. *PLoS Med* **2016**; 13(10): e1002152.
3. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. *The Lancet Infectious Diseases* **2003**; 3(9): 578-90.
4. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. *Arch Intern Med* **2003**; 163(9): 1009-21.
5. Hensel RL, Kempker RR, Tapia J, Oladele A, Blumberg HM, Magee MJ. Increased risk of latent tuberculosis infection among persons with pre-diabetes and diabetes mellitus. *Int J Tuberc Lung Dis* **2016**; 20(1): 71-8.
6. Jeon CY, Murray MB, Baker MA. Managing tuberculosis in patients with diabetes mellitus: why we care and what we know. *Expert Rev Anti Infect Ther* **2012**; 10(8): 863-8.
7. Kapur A, Harries AD. The double burden of diabetes and tuberculosis - public health implications. *Diabetes research and clinical practice* **2013**; 101(1): 10-9.
8. Ronacher K, Joosten SA, Van Crevel R, Dockrell HM, Walzl G, Ottenhoff TH. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. *Immunol Rev* **2015**; 264(1): 121-37.
9. Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. *European journal of immunology* **2014**; 44(3): 617-26.
10. Restrepo BI, Schlesinger LS. Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus. *Tuberculosis* **2013**; 93: S10-S4.
11. Jeon CY, Harries AD, Baker MA, et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. *Tropical medicine & international health : TM & IH* **2010**; 15(11): 1300-14.

12. Harries AD, Kumar AM, Satyanarayana S, et al. Diabetes mellitus and tuberculosis: programmatic management issues. *Int J Tuberc Lung Dis* **2015**; 19(8): 879-86.
13. Lönnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. *The Lancet Diabetes & Endocrinology* **2014**; 2(9): 730-9.
14. Harries AD, Murray MB, Jeon CY, et al. Defining the research agenda to reduce the joint burden of disease from diabetes mellitus and tuberculosis. *Tropical medicine & international health : TM & IH* **2010**; 15(6): 659-63.
15. Odone A, Houben RM, White RG, Lonnroth K. The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. *The lancet Diabetes & endocrinology* **2014**; 2(9): 754-64.
16. International Diabetes Federation. *IDF Diabetes Atlas Seventh Edition 2015*. **2015**; 7th: 1-144.
17. Lee MR, Huang YP, Kuo YT, et al. Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* **2016**.
18. Miramontes R, Hill AN, Yelk Woodruff RS, et al. Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012. *PloS one* **2015**; 10(11): e0140881.
19. Ghassemieh BJ, Attia EF, Koelle DM, Mancuso JD, Narita M, Horne DJ. Latent Tuberculosis Infection Test Agreement in the National Health and Nutrition Examination Survey. *American journal of respiratory and critical care medicine* **2016**; 194(4): 493-500.
20. Johnson CL, Dohrmann SM, Burt VL, Mohadjer LK. National Health and Nutrition Examination Survey: Sample design, 2011-2014. *Vital Health Stat* **2014**; 2(162).

21. CDC. National Health and Nutrition Examination Survey: Analytic Guidelines, 2011-2012. **2013**: 1-13.
22. CDC. 2011-2012 Laboratory Data Overview. National Center for Health Statistics. Available at: <https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/overviewlab.aspx?BeginYear=2011>. Accessed 26 July 2017.
23. American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care **2015**; 38 Suppl: S8-S16.
24. CDC. National Health and Nutrition Examination Survey: 2011-2012 Data Documentation, Codebook, and Frequencies. Atlanta, GA: National Center for Health Statistics **2013**.
25. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep **2010**; 59(RR-5): 1-25.
26. CDC. About Adult BMI. **2015**. Available at: https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html. Accessed 26 July 2017.
27. Kahende JW, Adhikari B, Maurice E, Rock V, Malarcher A. Disparities in health care utilization by smoking status--NHANES 1999-2004. International journal of environmental research and public health **2009**; 6(3): 1095-106.
28. National Kidney Foundation. ACR. **2016**. Available at: https://www.kidney.org/kidneydisease/siemens_hcp_acr. Accessed 26 July 2017.
29. National Cholesterol Education Program. ATP III Guidelines At-A-Glance Quick Desk Reference. **2001**.c
30. NIH MedlinePlus. Cholesterol Levels: What You Need to Know. NIH: US National Library of Medicine **2012**. Available at:

- <https://medlineplus.gov/magazine/issues/summer12/articles/summer12pg6-7.html>. Accessed 26 July 2017.
31. SAS Institute Inc. PROC SURVEYMEANS Statement. SAS/STAT(R) 92 User's Guide, Second Edition. Available at:
https://support.sas.com/documentation/cdl/en/statug/63033/HTML/default/viewer.htm#statug_surveymeans_sect007.htm. Accessed 26 July 2017.
32. Greenland S, Pearl J, Robins JM. Causal diagrams epidemiologic research. *Epidemiology* **1999**; 10(1): 37-48.
33. SAS Institute Inc. SAS/STAT Software: Survey Analysis. SAS Support. Available at:
<https://support.sas.com/rnd/app/stat/procedures/SurveyAnalysis.html>. Accessed 26 July 2017.
34. Mancuso JD, Diffenderfer JM, Ghassemieh BJ, Horne DJ, Kao TC. The Prevalence of Latent Tuberculosis Infection in the United States. *American journal of respiratory and critical care medicine* **2016**; 194(4): 501-9.
35. Kim JS, Ryu MJ, Byun EH, et al. Differential immune response of adipocytes to virulent and attenuated *Mycobacterium tuberculosis*. *Microbes and infection / Institut Pasteur* **2011**; 13(14-15): 1242-51.
36. Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. *Immunology* **2015**; 144(2): 171-85.
37. Grossmann V, Schmitt VH, Zeller T, et al. Profile of the Immune and Inflammatory Response in Individuals With Prediabetes and Type 2 Diabetes. *Diabetes Care* **2015**; 38(7): 1356-64.
38. American Diabetes Association. Diagnosing Diabetes and Learning About Prediabetes. **2016**. Available at: <http://www.diabetes.org/are-you-at-risk/prediabetes/?referrer=https://www.google.com/>. Accessed 26 July 2017.

39. Blumberg HM, Kempker RR. Interferon-gamma release assays for the evaluation of tuberculosis infection. *JAMA* **2014**; 312(14): 1460-1.
40. MedlinePlus. Bilirubin blood test. NIH: US National Library of Medicine **2015**. Available at: <https://medlineplus.gov/ency/article/003479.htm>. Accessed 26 July 2017.

Table 1: Weighted prevalence of diabetes and prediabetes among the civilian, non-institutionalized

United States population, adults 20 years and older, 2011-2012

Participant Characteristics	Totals for Population N=4,958 % (95% CI)	Diabetes ^a % (95% CI) 11.4 (9.8-13.0)	Prediabetes ^b % (95% CI) 22.1 (20.5-23.8)	No Diabetes % (95% CI) 66.5 (64.2-68.8)	p-value ^c
Age (years)					
20 – 34	27.5 (23.1-31.9)	2.0 (1.2-2.8)	9.0 (7.3-10.7)	89.0 (87.0-91.0)	<0.01
35 – 64	54.9 (51.8-57.9)	12.4 (10.2-14.6)	24.0 (20.6-27.3)	63.6 (60.0-67.1)	
≥65	17.6 (15.3-19.9)	22.9 (19.8-25.9)	36.9 (32.8-41.0)	40.3 (34.8-45.7)	
BMI^d					
<18.5	1.8 (1.3-2.2)	4.2 (0-8.8)	8.0 (2.1-13.9)	87.8 (81.0-94.5)	<0.01
18.5 – 24.9	29.4 (26.1-32.6)	5.1 (3.4-6.9)	17.6 (14.0-21.2)	77.3 (72.9-81.7)	
25.0-29.9	33.5 (30.7-36.3)	7.7 (6.7-8.6)	22.8 (19.2-26.3)	69.6 (66.1-73.0)	
≥30.0	35.4 (32.3-38.5)	20.4 (17.3-23.5)	26.1 (23.1-29.1)	53.5 (49.3-57.6)	
Foreign Born^e					
No	82.1 (77.9-86.3)	11.0 (9.2-12.8)	22.0 (20.0-23.9)	67.0 (64.4-69.6)	0.12
Yes	17.9 (13.7-22.1)	13.2 (11.3-15.0)	22.7 (19.8-25.6)	64.1 (61.1-67.1)	
LTBI^f					
Positive	5.9 (4.9-7.0)	22.2 (16.6-27.8)	25.9 (22.1-29.7)	51.9 (45.8-58.0)	<0.01
Negative	94.1 (93.0-95.1)	10.7 (9.0-12.4)	21.9 (20.3-23.6)	67.4 (65.0-69.8)	
TST^g					
Positive	4.7 (3.0-6.4)	15.5 (9.4-21.6)	29.2 (18.5-39.9)	55.3 (46.6-63.9)	0.11
Negative	95.3 (93.6-97.0)	11.3 (9.7-13.0)	22.2 (20.2-24.2)	66.5 (64.0-69.9)	
HbA1c (%)^h					
<5.7	67.1 (64.9-69.3)	0.91 (0.50-1.3)	0 (0-0)	99.1 (98.7-99.5)	
5.7-6.4	24.8 (22.7-26.9)	10.8 (7.8-13.8)	89.2 (86.2-92.2)	0 (0-0)	
≥6.5	8.1 (6.9-9.3)	100 (100-100)	0 (0-0)	0 (0-0)	
Education					
<9 th Grade	5.7 (4.5-7.0)	25.2 (18.2-32.2)	29.2 (24.0-34.4)	45.6 (39.3-52.0)	<0.01
9 th – 12 th	10.5 (7.6-13.5)	15.0 (13.5-16.5)	26.6 (21.9-31.2)	58.4 (53.7-63.1)	
HS Grad/GED	20.2 (17.2-23.2)	14.7 (11.1-18.2)	27.2 (21.1-33.2)	58.2 (52.1-64.2)	
Some College	32.2 (29.0-35.3)	10.0 (8.3-11.7)	20.7 (17.0-24.5)	69.3 (66.1-72.5)	
≥College Grad	31.4 (26.1-36.7)	7.0 (4.2-9.8)	17.5 (14.2-20.8)	75.5 (70.9-80.1)	
Race/Ethnicity					
Hispanic	14.7 (9.2-20.2)	13.1 (10.5-15.6)	21.8 (19.2-24.3)	65.1 (62.1-68.2)	<0.01
NH White	68.8 (60.2-77.3)	9.4 (7.6-11.2)	20.9 (18.4-23.5)	69.6 (66.2-73.1)	
NH Black	11.3 (6.5-16.1)	17.9 (14.2-21.6)	30.0 (27.1-32.9)	52.1 (48.7-55.6)	
NH Asian	5.2 (3.2-7.1)	12.9 (9.8-16.0)	22.9 (18.3-27.5)	64.2 (57.4-71.0)	
Sex					
Female	52.2 (50.5-53.9)	11.1 (9.3-12.8)	22.2 (19.7-24.8)	66.7 (63.5-69.9)	0.82
Male	47.8 (46.1-49.5)	11.8 (9.7-13.8)	22.0 (20.0-24.0)	66.3 (63.3-69.2)	
Smoking Statusⁱ					
Current	19.5 (17.2-21.7)	10.5 (8.8-12.3)	27.1 (21.4-32.8)	62.4 (57.0-67.7)	<0.01
Former	24.3 (21.6-26.9)	15.2 (11.7-18.8)	23.6 (20.2-26.9)	61.2 (56.3-66.1)	
Never	56.2 (53.3-59.1)	10.2 (8.2-12.2)	20.0 (17.4-22.7)	69.8 (66.6-73.0)	
Previous TB^j					
Yes	0.40 (0.22-0.58)	7.3 (0-16.3)	30.8 (14.2-47.4)	61.9 (45.0-78.8)	0.59

No	99.6 (99.4-99.8)	11.4 (9.8-13.0)	22.1 (20.4-23.8)	66.5 (64.1-68.8)	
TB Meds^k					
Yes	0.24 (0.12-0.36)	4.7 (0-12.2)	32.8 (4.4-61.2)	62.5 (32.5-92.5)	0.63
No	99.8 (99.6-99.9)	11.4 (9.8-13.0)	22.1 (20.4-23.8)	66.5 (64.1-68.8)	
Ratio of Family Income to Poverty^l					
0-0.99	17.2 (13.8-20.6)	14.9 (11.6-18.1)	20.5 (15.6-25.3)	64.7 (57.9-71.5)	
1-1.99	21.1 (18.1-24.2)	14.9 (12.3-17.5)	24.6 (20.4-28.8)	60.5 (55.3-65.7)	<0.01
2-2.99	14.3 (12.1-16.4)	11.9 (7.9-15.8)	24.0 (19.1-28.9)	64.1 (57.8-70.5)	
3-3.99	12.1 (9.1-15.1)	9.4 (7.2-11.6)	18.5 (14.6-22.4)	72.1 (67.7-76.6)	
4-4.99	10.7 (8.5-12.9)	13.6 (5.6-21.5)	17.8 (13.3-22.2)	68.7 (60.0-77.3)	
≥5	24.6 (19.6-29.6)	5.4 (3.0-7.8)	21.5 (17.2-25.9)	73.1 (67.1-79.0)	
Albumin/Creatinine Ratio (mg/g)^m					
<30	90.4 (89.2-91.6)	9.2 (7.9-10.5)	21.9 (20.1-23.8)	68.9 (66.6-71.2)	<0.01
30 – 300	8.3 (7.4-9.2)	28.7 (23.5-33.9)	24.8 (22.4-27.1)	46.5 (40.5-52.5)	
>300	1.3 (0.94-1.7)	46.9 (33.7-60.1)	21.0 (8.6-33.3)	32.1 (16.2-48.1)	
HepB Core Abⁿ					
Positive	4.6 (3.6-5.5)	19.1 (13.1-25.1)	28.0 (20.3-35.7)	52.9 (46.2-59.6)	<0.01
Negative	95.4 (94.5-96.4)	10.8 (9.3-12.3)	21.7 (19.9-23.6)	67.5 (65.2-69.8)	
HepB Surface Ag^o					
Positive	0.34 (0.20-0.48)	8.6 (1.4-15.8)	27.7 (12.9-42.4)	63.8 (45.9-81.6)	<0.01
Negative	99.7 (99.5-99.8)	11.2 (9.7-12.7)	22.0 (20.3-23.7)	66.9 (64.6-69.1)	
HepC Ab (confirmed)^p					
Positive	1.7 (1.0-2.3)	19.8 (7.1-32.5)	17.5 (11.4-23.6)	62.7 (46.9-78.4)	0.01
Negative	98.3 (97.7-99.0)	11.1 (9.7-12.5)	22.0 (20.2-23.9)	66.9 (64.6-69.2)	
Self-reported Hypertension^q					
Yes	31.5 (28.4-34.7)	23.3 (20.8-25.9)	29.2 (26.6-31.8)	47.5 (44.1-50.8)	<0.01
No	68.5 (65.3-71.6)	5.9 (4.8-7.0)	18.9 (17.2-20.6)	75.2 (73.2-77.3)	
Total Bilirubin (mg/dL)^r					
Normal	98.7 (98.0-99.4)	11.2 (9.6-12.7)	22.1 (20.5-23.7)	66.7 (64.4-69.1)	0.11
Not Normal	1.3 (0.59-2.0)	5.3 (0.21-10.4)	14.3 (1.7-26.9)	80.4 (67.0-93.9)	
Total Cholesterol (mg/dL)^s					
<200	56.9 (55.0-58.8)	12.7 (11.2-14.1)	19.1 (17.0-21.2)	68.2 (65.4-71.0)	<0.01
200-239	30.1 (28.4-31.7)	8.9 (6.6-11.3)	24.4 (20.8-28.1)	66.6 (61.9-71.3)	
≥240	13.0 (11.4-14.7)	9.6 (6.4-12.9)	29.2 (24.9-33.7)	61.1 (56.1-66.1)	
HDL Cholesterol (mg/dL)^t					
<40	17.4 (14.7-20.1)	18.9 (13.4-24.5)	25.4 (22.2-28.6)	55.7 (48.6-62.7)	<0.01
40 – 59	54.7 (51.9-57.6)	11.8 (10.5-13.1)	23.3 (21.1-25.5)	64.9 (62.3-67.5)	
≥60	27.9 (25.5-30.2)	5.1 (3.2-6.9)	17.5 (13.4-21.6)	77.4 (72.7-82.1)	

Table 1 Abbreviations: BMI-body mass index; LTBI-latent TB infection; HbA1c-glycated hemoglobin; TST-

tuberculin skin test; QFT-GIT-QuantiFERON®-TB Gold In-Tube; NH-Non-Hispanic; Anti-HBc-hepatitis B core

antibody; HBsAg-hepatitis B surface antigen; Anti-HCV-hepatitis C antibody

- a: Diabetes determined by self-report (answered “yes” to having been told by a doctor or health professional that he/she had diabetes) and according to American Diabetes Association guidelines[23]; participants who self-reported diabetes were classified as having diabetes regardless of HbA1c.
- b: Prediabetes determined according to American Diabetes Association guidelines[23].
- c: All p-values obtained using Rao-Scott chi-square.
- d: BMI categories defined according to CDC guidelines[26].
- e: Foreign born individuals include those who reported being born in one of the five United States territories.
- f: Positive LTBI defined by positive QFT-GIT result; negative LTBI defined by negative QFT-GIT result.
- g: Positive TST defined as an induration >10mm[24].
- h: HbA1c categories determined according to American Diabetes Association guidelines[23].
- i: Current smokers defined as those who self-reported having smoked at least 100 cigarettes in their lifetime and currently smoking every day or some days; former smokers defined as those who self-reported having smoked at least 10 cigarettes in their lifetime but are not currently smoking at all; participants who reported not having smoked at least 100 cigarettes in their lifetime defined as never having smoked[24, 27].
- j: Determined by participant’s response to “Were you ever told that you had active tuberculosis or TB?”[24]
- k: Determined by participant’s response to “Were you ever prescribed any medicine to treat active tuberculosis or TB?”; specific medicine type not asked[24].
- l: Ratio of family income to poverty guidelines; poverty guidelines as determined by the Department of Health and Human Services used as poverty measure to calculate ratio of family income to poverty[24].
- m: Categories for Albumin/Creatinine Ratio (ACR) defined according to National Kidney Foundation guidelines for albuminuria categories in chronic kidney disease (CKD)[28].
- n: Anti-HBc; positive/negative result determined by response to VITROS Anti-HBc assay[24].
- o: HBsAg; only tested if participant had positive result for anti-HBc; positive/negative result determined by response to VITROS HBsAg assay; participants that tested negative for anti-HBc also coded as negative for HBsAg[24].
- p: Anti-HCV; participants first screened for anti-HCV using VITROS Anti-HCV assay; participants with repeatedly positive reactions to Anti-HCV assay are then confirmed positive using the Chiron RIBA HCV 3.0 Strip[24].
- q: Hypertension determined by self-report (answered “yes” to having been told by a doctor or health professional that he/she had hypertension/high blood pressure)[24].

r: Categories for Total Bilirubin defined according to Medline Plus guidelines[40].

s: Categories for Total Cholesterol defined according to National Institute of Health guidelines[29].

t: Categories for HDL Cholesterol defined according to Medline Plus guidelines as follows[30].

Table 2: Weighted prevalence of latent tuberculosis infection (LTBI) among the civilian, non-institutionalized United States population, adults 20 years and older, 2011-2012

Participant Characteristics	Totals for Population N=4,958 % (95% CI)	LTBI Positive ^a % (95% CI) 5.9 (4.9-7.0)	LTBI Negative ^b % (95% CI) 94.1 (93.0-95.1)	p-value ^c
Age (years)				
20 – 34	27.5 (23.1-31.9)	3.3 (2.5-4.1)	96.7 (95.9-97.5)	<0.01
35 – 64	54.9 (51.8-57.9)	6.4 (4.7-8.1)	93.6 (91.9-95.3)	
≥65	17.6 (15.3-19.9)	8.8 (6.6-10.9)	91.2 (89.1-93.4)	
BMI^d				
<18.5	1.8 (1.3-2.2)	7.9 (2.0-13.9)	92.1 (86.1-98.0)	0.68
18.5 – 24.9	29.4 (26.1-32.6)	6.4 (4.5-8.3)	93.6 (91.7-95.5)	
25.0-29.9	33.5 (30.7-36.3)	5.6 (4.3-6.9)	94.4 (93.1-95.7)	
≥30.0	35.4 (32.3-38.5)	5.8 (4.7-7.0)	94.2 (93.0-95.3)	
Foreign Born^e				
No	82.1 (77.9-86.3)	3.5 (2.5-4.6)	96.5 (95.4-97.5)	<0.01
Yes	17.9 (13.7-22.1)	17.2 (14.3-20.0)	82.8 (80.0-85.7)	
TST^f				
Positive	4.7 (3.0-6.4)	46.2 (40.1-52.4)	53.8 (47.6-59.9)	<0.01
Negative	95.3 (93.6-97.0)	3.6 (2.7-4.4)	96.4 (95.6-97.3)	
Diabetes^g				
No Diabetes	66.5 (64.2-68.8)	4.6 (3.7-5.6)	95.4 (94.4-96.3)	<0.01
Prediabetes	22.1 (20.5-23.8)	7.0 (5.2-8.7)	93.0 (91.3-94.8)	
Diabetes	11.4 (9.8-13.0)	11.6 (7.9-15.3)	88.4 (84.7-92.1)	
HbA1c (%)^h				
<5.7	67.1 (64.9-69.3)	4.7 (3.7-5.6)	95.3 (94.4-96.3)	<0.01
5.7-6.4	24.8 (22.7-26.9)	7.7 (6.0-9.5)	92.3 (90.5-94.0)	
≥6.5	8.1 (6.9-9.3)	10.9 (7.1-14.8)	89.1 (85.2-92.9)	
Education				
<9 th Grade	5.7 (4.5-7.0)	17.9 (13.2-22.7)	82.1 (77.3-86.8)	<0.01
9 th – 12 th	10.5 (7.6-13.5)	7.7 (5.4-10.0)	92.3 (90.0-94.6)	
HS Grad/GED	20.2 (17.2-23.2)	7.1 (4.7-9.5)	92.9 (90.5-95.3)	
Some College	32.2 (29.0-35.3)	3.5 (2.2-4.7)	96.5 (95.3-97.8)	
≥College Grad	31.4 (26.1-36.7)	5.0 (3.4-6.6)	95.0 (93.4-96.6)	
Race/Ethnicity				
Hispanic	14.7 (9.2-20.2)	12.9 (10.4-15.4)	87.1 (84.6-89.6)	<0.01
NH White	68.8 (60.2-77.3)	3.1 (2.2-4.1)	96.9 (95.9-97.8)	
NH Black	11.3 (6.5-16.1)	8.0 (6.0-9.9)	92.0 (90.1-94.0)	
NH Asian	5.2 (3.2-7.1)	20.3 (16.8-23.8)	79.7 (76.2-83.4)	
Sex				
Female	52.2 (50.5-53.9)	5.0 (3.9-6.2)	95.0 (93.8-96.1)	<0.01
Male	47.8 (46.1-49.5)	6.9 (5.7-8.2)	93.1 (91.8-94.3)	
Smoking Statusⁱ				
Current	19.5 (17.2-21.7)	6.7 (4.3-9.1)	93.3 (90.9-95.7)	0.15
Former	24.3 (21.6-26.9)	7.1 (4.8-9.5)	92.9 (90.5-95.2)	
Never	56.2 (53.3-59.1)	5.2 (4.2-6.1)	94.8 (93.9-95.8)	
Previous TB^j				

Yes	0.40 (0.22-0.58)	42.7 (24.1-61.2)	57.3 (38.8-75.9)	<0.01
No	99.6 (99.4-99.8)	5.8 (4.8-6.8)	94.2 (93.2-95.2)	
TB Meds^k				
Yes	0.24 (0.12-0.36)	48.2 (24.6-71.7)	51.8 (28.3-75.4)	<0.01
No	99.8 (99.6-99.9)	5.8 (4.8-6.8)	94.2 (93.2-95.2)	
Ratio of Family Income to Poverty^l				
0-0.99	17.2 (13.8-20.6)	8.5 (6.3-10.7)	91.5 (89.3-93.7)	<0.01
1-1.99	21.1 (18.1-24.2)	7.8 (6.1-9.5)	92.2 (90.5-93.9)	
2-2.99	14.3 (12.1-16.4)	5.4 (2.3-8.5)	94.6 (91.5-97.7)	
3-3.99	12.1 (9.1-15.1)	4.7 (2.7-6.6)	95.3 (93.4-97.3)	
4-4.99	10.7 (8.5-12.9)	2.9 (0.94-4.9)	97.1 (95.1-99.1)	
≥5	24.6 (19.6-29.6)	4.1 (2.3-5.9)	95.9 (94.1-97.7)	
Albumin/Creatinine Ratio (mg/g)^m				
<30	90.4 (89.2-91.6)	5.7 (4.6-6.8)	94.3 (93.2-95.4)	0.01
30 – 300	8.3 (7.4-9.2)	7.6 (4.3-10.8)	92.4 (89.2-95.7)	
>300	1.3 (0.94-1.7)	12.9 (6.7-19.2)	87.1 (80.8-93.3)	
HepB Core Abⁿ				
Positive	4.6 (3.6-5.5)	18.0 (11.6-24.4)	82.0 (75.6-88.4)	<0.01
Negative	95.4 (94.5-96.4)	5.3 (4.3-6.3)	94.7 (93.7-95.7)	
HepB Surface Ag^o				
Positive	0.34 (0.20-0.48)	23.0 (8.2-37.7)	77.0 (62.3-91.8)	<0.01
Negative	99.7 (99.5-99.8)	5.8 (4.8-6.8)	94.2 (93.2-95.2)	
HepC Ab (confirmed)^p				
Positive	1.7 (1.0-2.3)	5.1 (0.60-9.6)	94.9 (90.4-99.4)	0.71
Negative	98.3 (97.7-99.0)	5.9 (4.9-6.9)	94.1 (93.1-95.1)	
Self-reported Hypertension^q				
Yes	31.5 (28.4-34.7)	7.3 (5.6-9.0)	92.7 (91.0-94.4)	<0.01
No	68.5 (65.3-71.6)	5.3 (4.3-6.3)	94.7 (93.7-95.7)	
Total Bilirubin (mg/dL)^r				
Normal	98.7 (98.0-99.4)	5.9 (4.9-6.9)	94.1 (93.1-95.1)	0.45
Not Normal	1.3 (0.59-2.0)	3.6 (0-8.7)	96.4 (91.3-100)	
Total Cholesterol (mg/dL)^s				
<200	56.9 (55.0-58.8)	5.8 (4.7-6.9)	94.2 (93.1-95.3)	0.74
200-239	30.1 (28.4-31.7)	6.2 (4.6-7.8)	93.8 (92.2-95.4)	
≥240	13.0 (11.4-14.7)	5.6 (4.0-7.1)	94.4 (92.9-96.0)	
HDL Cholesterol (mg/dL)^t				
<40	17.4 (14.7-20.1)	7.1 (5.2-9.0)	92.9 (91.0-94.8)	0.23
40 – 59	54.7 (51.9-57.6)	5.8 (4.8-6.8)	94.2 (93.2-95.2)	
≥60	27.9 (25.5-30.2)	5.3 (3.5-7.0)	94.7 (93.0-96.5)	

Table 2 Abbreviations: BMI-body mass index; LTBI-latent TB infection; HbA1c-glycated hemoglobin; TST-

tuberculin skin test; QFT-GIT-QuantiFERON®-TB Gold In-Tube; NH-Non-Hispanic; Anti-HBc-hepatitis B core antibody; HBsAg-hepatitis B surface antigen; Anti-HCV-hepatitis C antibody

- a: Positive LTBI defined by positive QFT-GIT result.
- b: Negative LTBI defined by negative QFT-GIT result.
- c: All p-values obtained using Rao-Scott chi-square.
- d: BMI categories defined according to CDC guidelines[26].
- e: Foreign born individuals include those who reported being born in one of the five United States territories.
- f: Positive TST defined as an induration >10mm[24].
- g: Diabetes status determined by self-report (answered “yes” to having been told by a doctor or health professional that he/she had diabetes) and according to American Diabetes Association guidelines; participants who self-reported diabetes were classified as having diabetes regardless of HbA1c.
- h: HbA1c categories determined according to American Diabetes Association guidelines[23].
- i: Current smokers defined as those who self-reported having smoked at least 100 cigarettes in their lifetime and currently smoking every day or some days; former smokers defined as those who self-reported having smoked at least 10 cigarettes in their lifetime but are not currently smoking at all; participants who reported not having smoked at least 100 cigarettes in their lifetime defined as never having smoked[24, 27].
- j: Determined by participant’s response to “Were you ever told that you had active tuberculosis or TB?”
- k: Determined by participant’s response to “Were you ever prescribed any medicine to treat active tuberculosis or TB?”; specific medicine type not asked.
- l: Ratio of family income to poverty guidelines; poverty guidelines as determined by the Department of Health and Human Services (HHS) used as poverty measure to calculate ratio of family income to poverty[24].
- m: Categories for Albumin/Creatinine Ratio (ACR) defined according to National Kidney Foundation guidelines for albuminuria categories in chronic kidney disease (CKD)[28].
- n: Anti-HBc; positive/negative result determined by response to VITROS Anti-HBc assay[24].
- o: HBsAg; only tested if participant had positive result for anti-HBc; positive/negative result determined by response to VITROS HBsAg assay; participants that tested negative for anti-HBc also coded as negative for HBsAg[24].
- p: Anti-HCV; participants first screened for anti-HCV using VITROS Anti-HCV assay; participants with repeatedly positive reactions to anti-HCV assay are then confirmed positive using the Chiron RIBA HCV 3.0 Strip[24].
- q: Hypertension determined by self-report (answered “yes” to having been told by a doctor or health professional that he/she had hypertension/high blood pressure)[24].

r: Categories for Total Bilirubin defined according to Medline Plus guidelines[40].

s: Categories for Total Cholesterol defined according to National Institutes of Health guidelines[29].

t: Categories for HDL Cholesterol defined according to Medline Plus guidelines[30].

Table 3: Multivariable models for odds of latent tuberculosis infection based on positive QFT-GIT result by diabetes status in the civilian, non-institutionalized United States population aged 20 years and older, 2011-2012

Models	Crude Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI) ^a
Model 1:		
No Diabetes ^b	1.00	1.00
Prediabetes	1.54 (1.24 – 1.91)	1.15 (0.90 – 1.47)
Diabetes	2.70 (1.76 – 4.14)	1.90 (1.15 – 3.14)
Model 2:		
No Diabetes ^c	1.00	1.00
Diabetes	2.38 (1.58 – 3.59)	1.80 (1.14 – 2.83)
Model 3:		
No Diabetes	1.00	1.00
Undiagnosed Diabetes ^d	3.06 (1.61 – 5.82)	1.96 (1.05 – 3.68)
Diagnosed Diabetes	2.22 (1.46 – 3.38)	1.75 (1.09 – 2.80)
Model 4: HbA1c (%) ^e		
<5.7%	1.00	1.00
5.7-6.4%	1.71 (1.33 – 2.19)	1.30 (0.96 – 1.75)
≥6.5%	2.50 (1.64 – 3.81)	1.67 (1.04 – 2.69)
Model 5: HbA1c (%)		
<5.7	1.00	1.00
5.7-6.4	1.71 (1.33 – 2.19)	1.30 (0.96 – 1.75)
6.5-7.5	2.44 (1.48 – 4.01)	1.66 (0.99 – 2.80)
7.6-8.5	3.12 (1.62 – 6.02)	1.96 (1.06 – 3.63)
>8.5	2.21 (1.08 – 4.51)	1.50 (0.70 – 3.22)

a: Models adjusted for age (categorized as 20-35 years, 35-65 years, and ≥65 years), sex (female, male), smoking status (current, former, never), history of active TB (yes, no), and foreign born status (yes, no).

b: Diabetes status determined by self-report (answered “yes” to having been told by a doctor or health professional that he/she had diabetes) and according to American Diabetes Association guidelines[23]; participants who self-reported diabetes were classified as having diabetes regardless of HbA1c.

c: Individuals classified as having prediabetes or no diabetes for Model 1 were classified as not having diabetes for Model 2.

d: Participants with diabetes who were unaware they had diabetes were classified as previously undiagnosed; these previously undiagnosed participants have no information for duration of diabetes[24].

e: Glycated hemoglobin (HbA1c) categories determined according to American Diabetes Association guidelines[23].

Bold indicates that the adjusted odds ratio (aOR) is statistically significant

Table 4: Weighted prevalence of latent tuberculosis (LTBI) infection among only those with diabetes^a in the civilian, non-institutionalized United States population, adults 20 years and older, 2011-2012

Participant Characteristics	Totals for Population N=793 % (95% CI)	LTBI Positive ^b % (95% CI) 11.6 (7.9-15.3)	LTBI Negative ^c % (95% CI) 88.4 (84.7-92.1)	p-value ^d
Age (years)				
20 – 34	4.8 (3.2-6.4)	9.2 (0-21.4)	90.8 (78.6-100)	0.71
35 – 64	59.9 (55.4-64.6)	10.9 (5.5-16.2)	89.1 (83.8-94.5)	
≥65	35.3 (30.8-39.8)	13.1 (9.0-17.3)	86.9 (82.7-91.0)	
Sex				
Female	50.7 (45.6-55.8)	11.1 (7.1-15.0)	88.9 (85.0-92.9)	0.59
Male	49.3 (44.2-54.4)	12.1 (7.6-16.6)	87.9 (83.4-92.4)	
Race/Ethnicity				
Hispanic	17.3 (9.5-25.2)	24.3 (12.4-36.2)	75.7 (63.8-87.6)	<0.01
NH White	58.4 (46.3-70.5)	6.9 (3.2-10.6)	93.1 (89.4-96.8)	
NH Black	18.3 (10.2-26.3)	11.7 (7.5-15.9)	88.3 (84.1-92.5)	
NH Asian	6.0 (3.4-8.7)	27.5 (19.0-35.9)	72.5 (64.1-81.0)	
Foreign Born^e				
No	79.3 (73.3-85.3)	6.8 (4.4-9.1)	93.2 (90.9-95.6)	<0.01
Yes	20.7 (14.7-26.7)	30.2 (18.8-41.6)	69.8 (58.4-81.2)	
Smoking Status^f				
Current	18.0 (14.7-21.3)	12.5 (7.1-17.8)	87.5 (82.2-92.9)	0.21
Former	32.2 (27.1-37.3)	14.5 (7.8-21.3)	85.5 (78.7-92.2)	
Never	49.9 (43.7-56.0)	9.4 (5.1-13.8)	90.6 (86.2-95.0)	
Diabetes Duration (years)^g				
Undiagnosed ^h	19.9 (15.3-24.4)	14.4 (6.7-22.2)	85.6 (77.8-93.3)	0.32
<1	4.8 (2.3-7.2)	3.6 (0-8.0)	96.4 (92.0-100)	
1-3	16.5 (11.2-21.7)	9.3 (3.1-15.6)	90.7 (84.4-96.9)	
4-10	26.0 (22.7-29.4)	11.1 (6.0-16.3)	88.9 (83.7-94.0)	
≥10	32.9 (26.7-39.0)	12.5 (7.3-17.7)	87.5 (82.3-92.7)	
Diabetes Diagnosis Status				
Undiagnosed	19.9 (15.3-24.4)	14.4 (6.7-22.2)	85.6 (77.8-93.3)	0.24
Diagnosed	80.1 (75.6-84.7)	10.9 (7.4-14.4)	89.1 (85.6-92.6)	
Taking insulin				
Yes	23.5 (18.4-28.5)	7.3 (3.1-11.4)	92.7 (88.6-96.9)	0.03
No	76.5 (71.5-81.6)	12.9 (8.5-17.3)	87.1 (82.7-91.5)	
How long taking insulin (months)ⁱ				
1-12	20.9 (13.9-27.9)	7.2 (0-15.5)	92.8 (84.5-100)	0.09
13-24	11.0 (4.7-17.4)	11.0 (0-29.4)	89.0 (70.6-100)	
25-36	6.3 (0-13.7)	23.0 (3.1-43.0)	77.0 (57.0-96.9)	
>36	61.8 (49.1-74.4)	4.7 (0.99-8.4)	95.3 (91.6-99.0)	
Oral Agents^j				
Yes	60.4 (55.1-65.6)	12.0 (7.5-16.4)	88.0 (83.6-92.5)	0.65
No	39.6 (34.4-44.9)	11.0 (6.8-15.2)	89.0 (84.8-93.2)	

HbA1c (%)^k				
<5.7	5.4 (3.1-7.6)	9.1 (2.3-16.0)	90.9 (84.0-97.7)	0.71
5.7-6.4	23.4 (17.1-29.8)	14.1 (5.9-22.4)	85.9 (77.6-94.1)	
6.5-7.5	34.8 (28.8-40.7)	10.7 (6.2-15.2)	89.3 (84.8-93.8)	
7.6-8.5	14.5 (10.2-18.8)	13.3 (5.3-21.3)	86.7 (78.7-94.7)	
>8.5	21.9 (17.7-26.1)	9.8 (3.9-15.7)	90.2 (84.3-96.1)	
HepB Core Ab^l				
Positive	7.8 (5.0-10.7)	20.8 (8.9-32.7)	79.2 (67.3-91.1)	0.04
Negative	92.2 (89.3-95.0)	11.0 (7.2-14.9)	89.0 (85.1-92.8)	
HepC Ab (confirmed)^m				
Positive	2.9 (0.80-5.1)	3.8 (0-10.4)	96.2 (89.6-100)	0.06
Negative	97.1 (94.9-99.2)	12.0 (8.3-15.8)	88.0 (84.2-91.7)	
Self-reported Hypertensionⁿ				
Yes	64.6 (60.8-68.3)	10.6 (6.7-14.5)	89.4 (85.5-93.3)	0.31
No	35.4 (31.7-39.2)	13.4 (7.4-19.4)	86.6 (80.6-92.6)	
Total Cholesterol (mg/dL)^o				
<200	64.6 (60.0-69.2)	10.4 (6.8-13.9)	89.6 (86.1-93.2)	0.43
200-239	24.1 (20.2-28.0)	14.9 (6.9-22.9)	85.1 (77.1-93.1)	
≥240	11.3 (7.4-15.1)	13.4 (1.8-24.9)	86.6 (75.1-98.2)	
HDL Cholesterol (mg/dL)^p				
<40	29.6 (21.9-37.2)	11.9 (6.2-17.6)	88.1 (82.4-93.8)	0.75
40-59	57.7 (49.7-65.7)	11.1 (6.7-15.5)	88.9 (84.5-93.3)	
≥60	12.7 (9.1-16.4)	14.5 (4.3-24.7)	85.5 (75.3-95.7)	

Table 4 Abbreviations: BMI-body mass index; LTBI-latent TB infection; HbA1c-glycated hemoglobin; TST-

tuberculin skin test; QFT-GIT-QuantIFERON®-TB Gold In-Tube; NH-Non-Hispanic; Anti-HBc-hepatitis B core antibody; Anti-HCV-hepatitis C antibody

a: Diabetes determined by self-report (answered “yes” to having been told by a doctor or health professional that he/she had diabetes) and according to American Diabetes Association guidelines as having an HbA1c (glycated hemoglobin) level ≥6.5%[23]; participants who self-reported diabetes were classified as having diabetes regardless of HbA1c.

b: Positive LTBI defined by positive QFT-GIT result.

c: Negative LTBI defined by negative QFT-GIT result.

d: All p-values obtained using Rao-Scott chi-square.

e: Foreign born individuals include those who reported being born in one of the five United States territories.

f: Current smokers defined as those who self-reported having smoked at least 100 cigarettes in their lifetime and currently smoking every day or some days; former smokers defined as those who self-reported having smoked at

least 10 cigarettes in their lifetime but are not currently smoking at all; participants who reported not having smoked at least 100 cigarettes in their lifetime defined as never having smoked[24, 27].

g: Refers to how long participant has known they have diabetes; this was calculated using the age of the participant and his/her response to the survey question regarding how old he/she was when a doctor or other health professional first told him/her that he/she had diabetes or sugar diabetes[24].

h: Participants with diabetes who were unaware they had diabetes were classified as previously undiagnosed; these previously undiagnosed participants have no information for duration of diabetes[24].

i: Among participants who answered “yes” to taking insulin.

j: Determined by response to survey question “Are you now taking diabetic pills to lower your blood sugar?”; specific medications not determined[24].

k: HbA1c categories determined according to American Diabetes Association guidelines[23].

l: Anti-HBc; positive/negative result determined by response to VITROS Anti-HBc assay[24].

m: Anti-HCV; participants first screened for anti-HCV using VITROS Anti-HCV assay; participants with repeatedly positive reactions to anti-HCV assay are then confirmed positive using the Chiron RIBA HCV 3.0 Strip[24].

n: Hypertension determined by self-report (answered “yes” to having been told by a doctor or health professional that he/she had hypertension/high blood pressure)[24].

o: Categories for Total Cholesterol defined according to National Institute of Health guidelines[29].

p: Categories for HDL Cholesterol defined according to Medline Plus guidelines[30].

Figure 1: Flow chart showing process of selection for NHANES 2011-2012 participants eligible for study, including the categorization of eligible participants by diabetes status; raw numbers and percentages not weighted for NHANES sampling methodology.

1: Valid latent TB status based on QFT-GIT result